{"organizations": [], "uuid": "b514df0f8136c1243e30d62b5c7ebd6590f9d395", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180503.html", "section_title": "Archive News &amp; Video for Thursday, 03 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aequus-receives-positive-fda-regul/brief-aequus-receives-positive-fda-regulatory-guidance-for-anti-nausea-patch-idUSFWN1SA0TU", "country": "US", "domain_rank": 408, "title": "Aequus Receives Positive FDA Regulatory Guidance For Anti-Nausea Patch", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.063, "site_type": "news", "published": "2018-05-03T20:49:00.000+03:00", "replies_count": 0, "uuid": "b514df0f8136c1243e30d62b5c7ebd6590f9d395"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aequus-receives-positive-fda-regul/brief-aequus-receives-positive-fda-regulatory-guidance-for-anti-nausea-patch-idUSFWN1SA0TU", "ord_in_thread": 0, "title": "Aequus Receives Positive FDA Regulatory Guidance For Anti-Nausea Patch", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "aequus receives positive fda regulatory guidance for anti-nausea patch", "sentiment": "negative"}, {"name": "aequus pharmaceuticals inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "co", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3 (Reuters) - Aequus Pharmaceuticals Inc:\n* AEQUUS RECEIVES POSITIVE FDA REGULATORY GUIDANCE FOR ANTI-NAUSEA PATCH\n* AEQUUS PHARMACEUTICALS INC - FDA HAS CONFIRMED THAT AN ABBREVIATED 505(B)(2) REGULATORY PATHWAY WOULD BE APPROPRIATE FOR SUBMISSION OF AQS1303\n* AEQUUS PHARMACEUTICALS - FDA INDICATED BIOEQUIVALENCE STUDY TO BRIDGE ORAL DICLEGIS(®) SAFETY AND EFFICACY DATA WITH AQS1303 IS LIKELY ACCEPTABLE\n* AEQUUS PHARMACEUTICALS INC - FDA HAS AGREED WITH AEQUUS’ PROPOSED CLINICAL PLAN FOR AQS1303\n* AEQUUS PHARMACEUTICALS-RECEIVED POSITIVE FEEDBACK FROM U.S. FDA ON ITS PRE-IND SUBMISSION FOR CO’S LONG-ACTING ANTI-NAUSEA TRANSDERMAL PATCH, AQS1303 Source text for Eikon:\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-03T20:49:00.000+03:00", "crawled": "2018-05-04T17:09:54.010+03:00", "highlightTitle": ""}